142 related articles for article (PubMed ID: 11719730)
1. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Nov; 70(5):439-45. PubMed ID: 11719730
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
3. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
5. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159
[TBL] [Abstract][Full Text] [Related]
7. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Kivistö KT; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2000 Dec; 50(6):591-5. PubMed ID: 11136298
[TBL] [Abstract][Full Text] [Related]
8. Effect of gemfibrozil on the pharmacokinetics of pioglitazone.
Deng LJ; Wang F; Li HD
Eur J Clin Pharmacol; 2005 Dec; 61(11):831-6. PubMed ID: 16283275
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
11. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Tornio A; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
[TBL] [Abstract][Full Text] [Related]
12. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
13. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
Wang JS; Wen X; Backman JT; Neuvonen PJ
J Pharmacol Exp Ther; 2002 Jul; 302(1):43-9. PubMed ID: 12065698
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
[TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Niemi M; Backman JT; Granfors M; Laitila J; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Oct; 46(10):1319-23. PubMed ID: 12898007
[TBL] [Abstract][Full Text] [Related]
16. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.
Lilja JJ; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2005 Apr; 59(4):433-9. PubMed ID: 15801938
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
18. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Karonen T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2011 Feb; 67(2):151-5. PubMed ID: 20931329
[TBL] [Abstract][Full Text] [Related]
19. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.
Karonen T; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
